Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 192-198

  Li, Jinpeng ^a   Liu, Hao ^a   Yu, Jieping ^a   Yu, Honggang ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Colon cancer; Doxorubicin chemoresistance; Epithelial mesenchymal transition; RNA interference; Transforming growth factor Smad4 signaling

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC ANTIBIOTIC; CADHERIN; SMAD4 PROTEIN; SMAD4 PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNAIL; VIMENTIN;

ARTICLE; CANCER RESISTANCE; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HCT116 CELL LINE; HUMAN; HUMAN CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; METABOLISM;

ANTIBIOTICS, ANTINEOPLASTIC; CADHERINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN;

EID: 84926616258     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3356     Document Type: Article

References (28)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 49: 1374-1403, 2013.
2. Cui R, Okada Y, Jang SG, et al: Common variant in 6q26-q27 is associated with distal colon cancer in an Asian population. Gut 60: 799-805, 2011.
3. Jonker DJ, Spithoff K, Maroun J, et al: Adjuvant systemic chemotherapy for stage II and III colon cancer after complete resection: An updated practice guideline. Clin Oncol (R Coll Radiol) 23: 314-322, 2011.
4. Colombo V, Lupi M, Falcetta F, Forestieri D, D Incalci M and Ubezio P: Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells. Cancer Chemoth Pharm 67: 369-379, 2011.
5. Arafa el-Sa, Zhu Q, Shah ZI, et al: Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat Res 706: 28-35, 2011.
6. Rosanò L, Cianfrocca R, Spinella F, et al: Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin a receptor pathway in ovarian carcinoma cells. Clin Cancer Res 17: 2350-2360, 2011.
7. Bastid J: EMT in carcinoma progression and dissemination: Facts, unanswered questions, and clinical considerations. Cancer Metast Rev 31: 277-283, 2012.
8. Canino C, Mori F, Cambria A, et al: SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene 31: 3148-3163, 2012.
9. Borthwick LA, Gardner A, De Soyza A, Mann DA and Fisher AJ: Transforming growth factor-β1 (TGF-β1) driven epithelial to mesenchymal transition (EMT) is accentuated by tumour necrosis factor α (TNFα) via crosstalk between the SMAD and NF-κB pathways. Cancer Microenviron 5: 45-57, 2012.
10. Davidson BL and McCray PB: Current prospects for RNA interference-based therapies. Nat Rev Genet 12: 329-340, 2011.
11. Huang X, Huang S, Zhang F, et al: Lentiviral-mediated Smad4 RNAi promotes SMMC-7721 cell migration by regulation of MMP-2, VEGF and MAPK signaling. Mol Med Rep 3: 295-299, 2010.
12. Lindner D: Animal models and the tumor microenvironment: Studies of tumor-host symbiosis. Semin Oncol 41, 146-155, 2014.
13. Nakasone ES, Askautrud HA, Kees T, et al: Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21: 488-503, 2012.
14. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
15. Xiong XB and Lavasanifar A: Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 5: 5202-5213, 2011.
16. Ghosh J, Das J, Manna P and Sil PC: The protective role of arjunolic acid against doxorubicin induced intracellular ROS dependent JNK-p38 and p53-mediated cardiac apoptosis. Biomaterials 32: 4857-4866, 2011.
17. Sims JT, Ganguly SS, Bennett H, Friend JW, Tepe J and Plattner R: Imatinib reverses doxorubicin resistance by affecting activation of STAT3-Dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PloS one 8: e55509, 2013.
18. Li QQ, Chen ZQ, Cao XX, et al: Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. Cell Death Differ 18: 16-25, 2011.
19. Sun L, Yao Y, Liu B, et al: MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 31: 432-445, 2012.
20. Tian M, Neil JR and Schiemann WP: Transforming growth factor-β and the hallmarks of cancer. Cell Signal 23: 951-962, 2011.
21. Javelaud D, Alexaki VI, Dennler S, Mohammad KS, Guise TA and Mauviel A: TGF-β/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Res 71: 5606-5610, 2011.
22. Lim MJ, Lin T and Jakowlew SB: Signaling mechanisms of transforming growth factor-β (TGF-β) in cancer: TGF-β induces apoptosis in lung cells by a Smad-dependent mechanism. In: Tumor Suppressor Genes. Cheng Y (ed). 1st edition. InTech, Rijeka, Croatia, p145, 2012.
23. Kang Y, Park M, Heo S, et al: The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells. Biochim Biophys Acta 1830: 2638-2648, 2013.
24. Micalizzi DS, Farabaugh SM and Ford HL: Epithelial-mesenchymal transition in cancer: Parallels between normal development and tumor progression. J Mammary Gland Biol 15: 117-134, 2010.
25. Smith AL, Iwanaga R, Drasin DJ, et al: The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 31: 5162-5171, 2012.
26. Fuxe J, Vincent T and de Herreros AG: Transcriptional crosstalk between TGFβ and stem cell pathways in tumor cell invasion: Role of EMT promoting Smad complexes. Cell Cycle 9: 2363-2374, 2010.
27. Hesling C, Fattet L, Teyre G, et al: Antagonistic regulation of EMT by TIF1γ and Smad4 in mammary epithelial cells. Embo Rep 12: 665-672, 2011.
28. Wang Y, Li W, Zang X, et al: MicroRNA-204-5p regulates epithelial-to-mesenchymal transition during human posterior capsule opacification by targeting SMAD4. Invest Ophth Vis Sci 54: 323-332, 2013.